welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
rareBlog

Catabasis Connection – Phase 3 Baseline Characteristics and Non-Ambulatory Trial Partnership

Catabasis Connection – Phase 3 Baseline Characteristics And Non-Ambulatory Trial Partnership
Catabasis Connection – Phase 3 Baseline Characteristics And Non-Ambulatory Trial Partnership
Josh Argall
Community Manager

Catabasis Connection – Issue 23, January 2020

The most recent edition of the Catabasis Connection features news on what’s next for edasalonexent. Some highlights include:

  • Initiation of a Phase 2 clinical trial, in partnership with Duchenne UK, to study edasalonexent in non-ambulatory boys and men, with plans to enroll in sites throughout the United Kingdom. Individuals enrolled in the trial will also have the option to transition to the GalaxyDMD open-label extension study of edasalonexent upon completion of their participation in the Phase 2 clinical trial.
  • PolarisDMD, a Phase 3 clinical trial studying edasalonexent, has completed enrollment. Top-line results are expected in the fourth quarter of 2020 and are anticipated to support filing a new drug application (NDA) with the U.S. Federal Drug Administration (FDA) in 2021.

Talk live with Catabasis at CureDuchenne Cares Workshops

These Workshops will also feature the CureDuchenne BioBank! Learn how your family’s sample donations can further Duchenne research.